Risk Factors for the Adverse Events after Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplantation Patients
- Authors
- Suh, Suk-Won; Lee, Kwang-Woong; Jeong, Jaehong; Kim, Hyeyoung; Yi, Nam-Joon; Suh, Kyung-Suk
- Issue Date
- Nov-2016
- Publisher
- KOREAN ACAD MEDICAL SCIENCES
- Keywords
- Once-daily Tacrolimus; Twice-daily Tacrolimus; Conversion; Liver Transplantation; Adverse Events
- Citation
- JOURNAL OF KOREAN MEDICAL SCIENCE, v.31, no.11, pp 1711 - 1716
- Pages
- 6
- Journal Title
- JOURNAL OF KOREAN MEDICAL SCIENCE
- Volume
- 31
- Number
- 11
- Start Page
- 1711
- End Page
- 1716
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/6495
- DOI
- 10.3346/jkms.2016.31.11.1711
- ISSN
- 1011-8934
1598-6357
- Abstract
- Despite the therapeutic equivalence between twice-daily and once-daily tacrolimus, patient safety after conversion is still a concern. We reviewed 218 liver transplantation (LT) patients who converted twice-daily to once-daily tacrolimus between May 2011 and January 2014. Thirty (13.8%) patients had adverse events after conversion, with a liver function test (LFT) abnormality being the most common adverse event (n = 17). Despite the decrease in serum tacrolimus of > 30% after conversion, none of the patients who were converted to a dosage ratio (once-daily tacrolimus dosage: twice-daily tacrolimus dosage) > 1 had an LFT abnormality. Most patients with an LFT abnormality improved after increasing the once-daily tacrolimus dosage (n = 2), returned to a previous medication, and/or added another immunosuppressant (n = 15). One patient had acute cellular rejection, which improved after steroid pulse treatment, and another patient had graft failure. In patients with a dosage ratio <= 1, the conversion time within 5 years after LT was the only significant risk factor for an LFT abnormality after conversion (odds ratio: 11.850, 95% confidence interval: 1.321-106.325, P = 0.027). In conclusion, the dosage ratio and time after LT should be carefully considered during conversion from twice-daily to once-daily tacrolimus.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/6495)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.